The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Assessing the clinical characteristics of lung adenosquamous carcinoma
Matthew Lee, MD, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, gives an overview of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS), a rare type of lung cancer. Studies have suggested that MET exon 14 skipping mutations are more common in LUAS compared to other forms of lung cancer. Elucidating such differences will be important to determine treatment strategies and immunotherapy responses. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
